Dr. Feng Tian is a senior associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he practices intellectual property law, focusing on patent prosecution, IP due diligence, and general intellectual property counseling. He has worked on patent-related matters in a variety of technical subject areas, including pharmaceuticals, artificial intelligence (AI)-assisted drug discovery, chemical formulations, radiopharmaceuticals, nucleic acids (including 5’-capped mRNA), cosmetic products, gene therapies, gene sequencing technologies, diagnostics, HealthTech, FoodTech, AgTech, medical devices, mechanical arts (including parking meters and three-dimensional (3D) printers), and green chemistry-based inventions.
Prior to attending law school, Feng worked as a patent agent at an IP boutique firm in Chicago and as a technical specialist at a general practice firm on the East Coast, where he drafted and prosecuted U.S. and foreign patent applications, as well as rendered freedom-to-operate opinions.
Before his legal career, Feng spent nine years as a medicinal chemist and project co-leader at a small biopharmaceutical company in Southern California, where he focused on finding small molecule therapeutic agents for cancer, liver diseases, and metabolic diseases.
Feng has co-authored eight peer-reviewed research articles and two posters. He is a co-inventor of 10 patents and patent applications.
Dr. Feng Tian is a senior associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he practices intellectual property law, focusing on patent prosecution, IP due diligence, and general intellectual property counseling. He has worked on patent-related matters in a variety of technical subject areas, including pharmaceuticals, artificial intelligence (AI)-assisted drug discovery, chemical formulations, radiopharmaceuticals, nucleic acids (including 5’-capped mRNA), cosmetic products, gene therapies, gene sequencing technologies, diagnostics, HealthTech, FoodTech, AgTech, medical devices, mechanical arts (including parking meters and three-dimensional (3D) printers), and green chemistry-based inventions.
Prior to attending law school, Feng worked as a patent agent at an IP boutique firm in Chicago and as a technical specialist at a general practice firm on the East Coast, where he drafted and prosecuted U.S. and foreign patent applications, as well as rendered freedom-to-operate opinions.
Before his legal career, Feng spent nine years as a medicinal chemist and project co-leader at a small biopharmaceutical company in Southern California, where he focused on finding small molecule therapeutic agents for cancer, liver diseases, and metabolic diseases.
Feng has co-authored eight peer-reviewed research articles and two posters. He is a co-inventor of 10 patents and patent applications.
- J.D., University of Virginia School of LawSemi-Finalist, 2014 National IP LawMeet
- Ph.D., Organic Chemistry, Michigan State UniversityRecipient, Harold Hart Endowed Fellowship
- M.S., Physical Chemistry, Peking University
- B.S., Chemistry, Peking University
- Member, American Chemical Society
- Bar of the District of Columbia
- State Bar of Virginia
- U.S. Patent and Trademark Office
- J.D., University of Virginia School of LawSemi-Finalist, 2014 National IP LawMeet
- Ph.D., Organic Chemistry, Michigan State UniversityRecipient, Harold Hart Endowed Fellowship
- M.S., Physical Chemistry, Peking University
- B.S., Chemistry, Peking University
- Member, American Chemical Society
- Bar of the District of Columbia
- State Bar of Virginia
- U.S. Patent and Trademark Office
Select Publications
- Co-author with D. Hoffmeister and C. Andres, "Digital Health: FDA Gives Nod to Multiple First-in Class Devices?" Cyberspace Lawyer, Vol. 23, Issue 1, January/February 2018
- Co-author, "Life Beyond FDA Clearance or Approval: The Reimbursement Challenge," The Life Sciences Report, Winter 2018
- Co-author, "Digital Health: FDA Gives Nod to Multiple First-in-Class Devices," WSGR Alert, December 21, 2017
- Co-author, "FDA Issues Final Guidance on 'Deciding When to Submit a 510(k) for a Change to an Existing Medical Device,'" WSGR Alert, November 13, 2017
- Co-author with Q. Dang, et al., "Discovery of a Series of Phosphonic Acid-Containing Thiazoles and Orally Bioavailable Diamide Prodrugs That Lower Glucose in Diabetic Animals Through Inhibition of Fructose-1,6-Bisphosphatase," 54(1) Journal of Medicinal Chemistry 153-65, 2011
- Co-author with Q. Dang, et al., "A Tandem Decarboxylation and Inverse Electron-demand Diels-Alder Reaction of Amino-thiophenecarboxylic Acids with 1,3,5-Triazines," 50(24) Tetrahedron Letter 2874-6, 2011
- Co-author with M.L. Mitchell, L.V. Lee, and C.-H. Wong, "Synthesis and Evaluation of Transition-state Analogue Inhibitors of a-1,3-Fucosyltransferase," 41(16) Angewandte Chemie International Edition 3041-4, 2002
- Co-author with M.E. Migaud and J.W. Frost, "myo-Inositol 1-phosphate Synthase: Does a Single Active-site Amino Acid Catalyze Multiple Proton Transfers?" 121(24) Journal of American Chemical Society 5795-6, 1999
- Co-author with J.L. Montchamp and J.W. Frost, "Inhibitor Ionization as a Determinant of Binding to 3-Dehydroquinate Synthase," 61(21) Journal of Organic Chemistry 7373-81, 1996
- Co-author with J.L. Montchamp, M.E. Hart, and J.W. Frost, "Butane 2,3-Bisacetal Protection of Vicinal Diequatorial Diols," 61(11) Journal of Organic Chemistry 3897-9, 1996
- Co-author with J.L. Montchamp and J.W. Frost, "Double Arbuzov Reaction of in Situ Generated Bis(trimethylsiloxy)phosphine with Dielectrophiles: Methodology for the Synthesis of Cyclic Phosphinic Acids," 60(19) Journal of Organic Chemistry 6076-81, 1995
Select Publications
- Co-author with D. Hoffmeister and C. Andres, "Digital Health: FDA Gives Nod to Multiple First-in Class Devices?" Cyberspace Lawyer, Vol. 23, Issue 1, January/February 2018
- Co-author, "Life Beyond FDA Clearance or Approval: The Reimbursement Challenge," The Life Sciences Report, Winter 2018
- Co-author, "Digital Health: FDA Gives Nod to Multiple First-in-Class Devices," WSGR Alert, December 21, 2017
- Co-author, "FDA Issues Final Guidance on 'Deciding When to Submit a 510(k) for a Change to an Existing Medical Device,'" WSGR Alert, November 13, 2017
- Co-author with Q. Dang, et al., "Discovery of a Series of Phosphonic Acid-Containing Thiazoles and Orally Bioavailable Diamide Prodrugs That Lower Glucose in Diabetic Animals Through Inhibition of Fructose-1,6-Bisphosphatase," 54(1) Journal of Medicinal Chemistry 153-65, 2011
- Co-author with Q. Dang, et al., "A Tandem Decarboxylation and Inverse Electron-demand Diels-Alder Reaction of Amino-thiophenecarboxylic Acids with 1,3,5-Triazines," 50(24) Tetrahedron Letter 2874-6, 2011
- Co-author with M.L. Mitchell, L.V. Lee, and C.-H. Wong, "Synthesis and Evaluation of Transition-state Analogue Inhibitors of a-1,3-Fucosyltransferase," 41(16) Angewandte Chemie International Edition 3041-4, 2002
- Co-author with M.E. Migaud and J.W. Frost, "myo-Inositol 1-phosphate Synthase: Does a Single Active-site Amino Acid Catalyze Multiple Proton Transfers?" 121(24) Journal of American Chemical Society 5795-6, 1999
- Co-author with J.L. Montchamp and J.W. Frost, "Inhibitor Ionization as a Determinant of Binding to 3-Dehydroquinate Synthase," 61(21) Journal of Organic Chemistry 7373-81, 1996
- Co-author with J.L. Montchamp, M.E. Hart, and J.W. Frost, "Butane 2,3-Bisacetal Protection of Vicinal Diequatorial Diols," 61(11) Journal of Organic Chemistry 3897-9, 1996
- Co-author with J.L. Montchamp and J.W. Frost, "Double Arbuzov Reaction of in Situ Generated Bis(trimethylsiloxy)phosphine with Dielectrophiles: Methodology for the Synthesis of Cyclic Phosphinic Acids," 60(19) Journal of Organic Chemistry 6076-81, 1995
Gamma acquired a controlling stake in Mirus Bio in 2021 and has worked closely with the company to support its growth and scale-up, including the launch of flagship products VirusGEN® GMP and RevIT™ AAV Enhancer for large-scale therapeutic adeno-associated virus and lentivirus production. The transaction is expected to be completed in the third quarter of 2024, subject to U.S. regulatory approvals, as well as other customary closing conditions.
- Privacy Policy
- Terms of Use
- Accessibility